Anvisa approves new HIV treatment

Get real time updates directly on you device, subscribe now.

Anvisa announced this Monday (29) that it has approved a new drug for the treatment of HIV. It combines two substances – lamivudine and dolutegravir sodium – in a single tablet.

According to the agency, the possibility of single doses action simplifies the treatment and adherence of patients to treatment.

According to the leaflet approved by Anvisa, the new drug reduces the amount of HIV in the body, keeping it at a low level. In addition, it promotes an increase in the count of CD4 cells, a type of white blood cell that plays an important role in maintaining a healthy immune (defence) system, helping to fight infections.

The drug may be indicated as a complete regimen for the treatment of infection by the human immunodeficiency virus type 1 (HIV-1) in adults and adolescents over 12 years old weighing at least 40 kg, with no history of previous antiretroviral treatment or in substitution for current antiretroviral regimen in virologically suppressed people.

Reference: CNN Brasil

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.